Want to see JP:4576 full AI Analyst Report?
Total Valuation
D.Western Therapeutics Institute has a market cap or net worth of ¥4.37B. The enterprise value is ¥2.55B.
Market Cap¥4.37B
Enterprise Value¥2.55B
Share Statistics
D.Western Therapeutics Institute has 57,483,414 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,483,414
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
D.Western Therapeutics Institute’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -30.02%.
Return on Equity (ROE)-0.44
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-30.02%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee20.40M
Profits Per Employee-33.27M
Employee Count19
Asset Turnover0.18
Inventory Turnover0.99
Valuation Ratios
The current PE Ratio of D.Western Therapeutics Institute is ―. D.Western Therapeutics Institute’s PEG ratio is 0.11.
PE Ratio―
PS Ratio11.87
PB Ratio3.21
Price to Fair Value3.21
Price to FCF-9.27
Price to Operating Cash Flow0.00
PEG Ratio0.11
Income Statement
In the last 12 months, D.Western Therapeutics Institute had revenue of 387.62M and earned -632.09M in profits. Earnings per share was -13.19.
Revenue387.62M
Gross Profit301.24M
Operating Income-619.87M
Pretax Income-630.49M
Net Income-632.09M
EBITDA-572.35M
Earnings Per Share (EPS)-13.19
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
D.Western Therapeutics Institute pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.26
52-Week Price Change-32.14%
50-Day Moving Average75.06
200-Day Moving Average92.80
Relative Strength Index (RSI)50.36
Average Volume (3m)623.89K
Important Dates
D.Western Therapeutics Institute upcoming earnings date is Aug 13, 2026, TBA (Not Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
D.Western Therapeutics Institute as a current ratio of 9.91, with Debt / Equity ratio of 45.21%
Current Ratio9.91
Quick Ratio9.48
Debt to Market Cap0.13
Net Debt to EBITDA1.93
Interest Coverage Ratio-70.32
Taxes
In the past 12 months, D.Western Therapeutics Institute has paid 1.59M in taxes.
Income Tax1.59M
Effective Tax Rate>-0.01
Enterprise Valuation
D.Western Therapeutics Institute EV to EBITDA ratio is -6.11, with an EV/FCF ratio of -7.04.
EV to Sales9.02
EV to EBITDA-6.11
EV to Free Cash Flow-7.04
EV to Operating Cash Flow-7.08
Balance Sheet
D.Western Therapeutics Institute has ¥1.54B in cash and marketable securities with ¥594.17M in debt, giving a net cash position of ¥945.66M billion.
Cash & Marketable Securities¥1.54B
Total Debt¥594.17M
Net Cash¥945.66M
Net Cash Per Share¥16.45
Tangible Book Value Per Share¥29.90
Margins
Gross margin is 82.23%, with operating margin of -159.92%, and net profit margin of -163.07%.
Gross Margin82.23%
Operating Margin-159.92%
Pretax Margin-162.66%
Net Profit Margin-163.07%
EBITDA Margin-147.66%
EBIT Margin-159.92%
Analyst Forecast
The average price target for D.Western Therapeutics Institute is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-33.99%
EPS Growth Forecast55.26%